These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
733 related articles for article (PubMed ID: 9815848)
1. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848 [TBL] [Abstract][Full Text] [Related]
2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A; Kumar R; Gupta NP Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [TBL] [Abstract][Full Text] [Related]
4. [The BTA stat test in the follow-up for bladder cancer]. Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117 [TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510 [TBL] [Abstract][Full Text] [Related]
6. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912 [TBL] [Abstract][Full Text] [Related]
7. Comparison of screening methods in the detection of bladder cancer. Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409 [TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669 [TBL] [Abstract][Full Text] [Related]
10. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196 [TBL] [Abstract][Full Text] [Related]
11. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Lee DH; Yang SC; Hong SJ; Chung BH; Kim IY Clin Cancer Res; 1998 Mar; 4(3):535-8. PubMed ID: 9533519 [TBL] [Abstract][Full Text] [Related]
12. [Quantitative analysis of telomerase activity in exfoliated urothelial cells for the diagnosis of bladder carcinoma]. Yokota K; Kanayama H; Kagawa S; Abe-Hashimoto J; Hirose M; Yoshimura T Nihon Rinsho; 1998 May; 56(5):1292-8. PubMed ID: 9613140 [TBL] [Abstract][Full Text] [Related]
13. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder. Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567 [TBL] [Abstract][Full Text] [Related]
14. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813 [TBL] [Abstract][Full Text] [Related]
15. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331 [TBL] [Abstract][Full Text] [Related]
16. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Müller M; Krause H; Heicappell R; Tischendorf J; Shay JW; Miller K Clin Cancer Res; 1998 Aug; 4(8):1949-54. PubMed ID: 9717824 [TBL] [Abstract][Full Text] [Related]
17. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma. Bian W; Xu Z Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565 [TBL] [Abstract][Full Text] [Related]
18. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429 [TBL] [Abstract][Full Text] [Related]
19. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993 [TBL] [Abstract][Full Text] [Related]
20. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]